InvestorsHub Logo
Followers 826
Posts 119567
Boards Moderated 14
Alias Born 09/05/2002

Re: DewDiligence post# 18102

Friday, 02/16/2018 5:46:22 PM

Friday, February 16, 2018 5:46:22 PM

Post# of 20689
MNTA 2018 News Flow

[Miscellaneous updates.]


Proprietary autoimmune program

1H18: Start phase-1 trial of M230, which is partnered with CSL (#msg-127656306).

2018: Report full dataset from M281 phase-1 trial at an unspecified medical conference. (Top-line data were reported in Jan 2018: #msg-137491062.)

2018 Start phase-1 trial of M254, a hyper-sialylated IVIG.


FoB program

Timing unknown: M923 (Humira FoB) partnership or divestiture.

1H18: Start phase-3 trial for M710 (Eylea FoB).

2018: Report reason for inability of M834 (Orencia FoB) to meet its phase-1 pharmacokinetic endpoint; start phase-1 do-over, if necessary.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”